CTSO250117P7500
- 0.00
- 0.000.00%
Cytosorbents Newsroom
Insider Purchase: Chief Financial Officer of $CTSO (CTSO) Buys 20,000 Shares
CytoSorbents to Raise Funds Through Rights Offering, Unlocking Up to $10M in Liquidity
Express News | Cytosorbents Announces Rights Offering
CytoSorbents Announces Rights Offering
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
Express News | D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target
Several Insiders Invested In Cytosorbents Flagging Positive News
CytoSorbents Hops on Alliance With Converge
Express News | Cytosorbents and Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment With Cytosorb in India
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment With CytoSorb in India
H.C. Wainwright Maintains Cytosorbents(CTSO.US) With Hold Rating, Maintains Target Price $1
Balanced Hold Rating Amid Revenue Miss and Strategic Initiatives at CytoSorbents
Cytosorbents Is Maintained at Buy by EF Hutton
Cytosorbents Price Target Maintained With a $10.00/Share by EF Hutton
CytoSorbents Corporation's Q3 2024 Financial Highlights
CytoSorbents Reports Q3 Adjusted EPS (8c), Consensus (6c)
Cytosorbents | 10-Q: Q3 2024 Earnings Report
Earnings Flash (CTSO) CYTOSORBENTS Reports Q3 Revenue $9.4M
Cytosorbents | 8-K: CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
Express News | Cytosorbents Reports Third Quarter 2024 Financial and Operational Results